Insilico Medicine

Generative AI platform for end-to-end drug discovery, from target identification to clinical trials

Enterprise·Technical·Powered by Insilico Medicine (proprietary LLLMs)·API available

Key strengths

End-to-end AI-driven drug discovery pipeline (target ID to clinical trials)Generative chemistry and biology AI (Chemistry42, Generative Biologics)Large Language of Life Models (LLLMs) for biomedical researchValidated therapeutic pipeline with programs in Phase I/II trialsMulti-modal platform covering disease modeling, molecule generation, and clinical prediction

Enterprise pricing

Cambridge, USA

Founded 2014

Get alerts when Insilico Medicine changes

Free. We'll email you when pricing, the free tier, API access or open-source status changes.

No ratings yet

Multi-omics target identification: Use PandaOmics to integrate transcriptomics, proteomics, and genomics datasets to rank and validate novel therapeutic targets for a given disease.
Generative small molecule design: Deploy Chemistry42 to generate, score, and optimize lead compounds against specified targets using reinforcement learning pipelines.
Biologic sequence design: Apply Generative Biologics to produce antibody or protein therapeutic candidates with desired binding and stability properties.
Clinical trial outcome prediction: Feed trial design parameters and historical data into inClinico to estimate Phase II/III success probabilities and optimize trial design.
Biomedical literature mining & hypothesis generation: Integrate Science42:DORA (LLM assistant) into research workflows to automate literature review, extract mechanistic insights, and draft scientific hypotheses.
AI benchmarking & model evaluation: Use MMAI Gym and Insilico Bench to benchmark internal or third-party ML models against standardized drug discovery tasks and published Insilico baselines.